Nocardia beijingensis: A Novel Isolate Affecting Immunocompromised Patients in the United States

Shylah M. Moore-Pardo
*University of South Florida*

Johonna Asquith
*University of South Florida*

Sadaf Aslam
*University of South Florida*, saslam@usf.edu

Cynthia Mayer
*Tampa General Hospital*

John Greene
*Moffitt Cancer Center*

See next page for additional authors

Follow this and additional works at: [https://digitalcommons.usf.edu/intmed_facpub](https://digitalcommons.usf.edu/intmed_facpub)

Scholar Commons Citation
Moore-Pardo, Shylah M.; Asquith, Johonna; Aslam, Sadaf; Mayer, Cynthia; Greene, John; and Alrabaa, Sally, "Nocardia beijingensis: A Novel Isolate Affecting Immunocompromised Patients in the United States" (2019). *Internal Medicine Faculty Publications*. 177.
[https://digitalcommons.usf.edu/intmed_facpub/177](https://digitalcommons.usf.edu/intmed_facpub/177)

This Article is brought to you for free and open access by the Internal Medicine at Digital Commons @ University of South Florida. It has been accepted for inclusion in Internal Medicine Faculty Publications by an authorized administrator of Digital Commons @ University of South Florida. For more information, please contact scholarcommons@usf.edu.
Disclosures. All authors: No reported disclosures.

1354. Nocardia beijingensis: A Novel Isolate Affecting Immunocompromised Patients in the United States
Shylah M. Moore-Pardo, MD1; Johonna Asquith, MD2; Sadaf Aslam, MD, MS3; Cynthia Mayer, DO4; John Greene, MD5; Sally Alrabaa, MD6; 1University of South Florida, Tampa, Florida; 2Tampa General Hospital, Tampa, Florida; 3Moffitt Cancer Center, Tampa, Florida; 4University of South Florida Morsani College of Medicine, Tampa, Florida

Session: 153. Mycobacteria Friday, October 4, 2019: 12:15 PM

Background. Nocardia species can cause localized or disseminated disease in humans. Infection results from direct inoculation or inhalation. In recent years, several new species have been identified via molecular methods. Further speciation is crucial as each organism has its own spectrum of disease and unique antibiotic susceptibility patterns. Immunosuppression, alcoholism, and certain lung diseases are well-established risk factors for nocardiosis. In fact, cases have incremented in association with increasing population of immunocompromised hosts as well as improved methods for detection and identification. Thus, Nocardia species may be considered opportunistic pathogens. Nocardia beijingensis was first isolated in 2001 by Wang et al from sewage soil in China. The first human infections were reported in Asia. Subsequently, cases were reported in Europe and a few cases have been described in the United States but it has been infrequently cited in the literature. Thus, not much is known about its spectrum of disease.

Methods. The primary objective of this study was to determine the risk factors and clinical manifestations of Nocardia beijingensis infection via retrospective chart review of 6 cases identified in Tampa General Hospital and Moffitt Cancer Center within a 5-year period. We aimed to evaluate the treatment used and the antibiotic susceptibility patterns of the isolates.

Results. All patients were immunocompromised (1/3 HIV/AIDS, 1/3 hematologic malignancy, 1/3 solid-organ transplant). Most were male (67%) and mean age of 48. Their underlying condition had lung involvement (67%). Throat, gum and furunculosis (OM) were atypical manifestations. Localized disease predominated. Combination therapy was preferred. Trimethoprim-sulfamethoxazole (TMP-SMX), Ceftriaxone, and carbapenems were mostly used. All isolates were susceptible to TMP-SMX. See Table 1.

Conclusion. This case series depicts clinical features, risk factors, and epidemiology of Nocardia beijingensis infections. Our observations suggest that it is a novel pathogen in the United States, affecting mainly immunocompromised hosts. Early detection, appropriate antibiotics, and surgery were keys in successful management. However, further studies are needed to further elucidate its pathogenesis.

Table 1. Results of TB testing:

<table>
<thead>
<tr>
<th>Period</th>
<th>Test used</th>
<th>Number of samples</th>
<th>Number of patients</th>
<th>Number of positive patients</th>
<th>% positive samples</th>
<th>% positive patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.1.2017 to 31.10.2017</td>
<td>Xpert MTB/RIF</td>
<td>461</td>
<td>344</td>
<td>10</td>
<td>2.17</td>
<td>2.91</td>
</tr>
<tr>
<td>1.1.2018 to 31.10.2018</td>
<td>Xpert MTB/RIF Ultra</td>
<td>571</td>
<td>372</td>
<td>25</td>
<td>4.38</td>
<td>6.72</td>
</tr>
</tbody>
</table>

Disclosures. All authors: No reported disclosures.

1355. Efficacy and Tolerability of Linezolid Adjunctive Treatment for Nontuberculous Mycobacterial Infection in Patients with Acquired Anti-Interferon-Gamma Autoantibody
Natthakit Chavapradit, MD; Yupin Suputtamongkol, MD; Nasikarn Angkasekwinai, MD; Pakpoom Phoompoyung, MD; Niphon Chirapapisan, MD; Suporn Foongladda, PhD; Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Krung Thep, Thailand

Session: 153. Mycobacteria Friday, October 4, 2019: 12:15 PM

Background. Despite a long duration of combined oral antimycobacterial drugs, relapse/ reinfection of nontuberculous mycobacteria (NTM) is common among patients with anti-interferon gamma autoantibodies (anti-IFN-γ auto-Abs).

Methods. We reported here, an interim analysis of the prospective study of 25 patients with anti-IFN-γ auto-Abs, who received oral linezolid (LZD) adjunctive treatment for their NTM infections, at Siriraj Hospital, Bangkok, Thailand, between December 2017 and April 2019.